Another Study for AstraZeneca

Nov 30, 2020

AstraZeneca may conduct another study to clear up confusion about results from a recent trial of its candidate SARS-CoV-2 vaccine, Bloomberg reports.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

Ancestry to Discontinue NGS-Based AncestryHealth Service
Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan
DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech
FDA Grants Emergency Use Authorization for SML Genetree Molecular Coronavirus Test
JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials

The Scan

Science Papers Examine Chronic Kidney Disease GWAS, Pneumonia Microbiome

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Quick Changes If Needed

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

Early Results on Johnson & Johnson's SARS-CoV-2 Vaccine

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

WHO Team Arrives

Investigators from the World Health Organization have arrived in China to look into the origins of SARS-CoV-2, NPR reports.

Menu